Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GAL-101 Salt · 1 trial · 1 indication
Number of participants who experience one or more adverse events following administration of GAL-101 salt or placebo.
| Arm | Type | Description |
|---|---|---|
| GAL-101 1200 mg | EXPERIMENTAL | Participants will receive two 600 mg GAL-101 salt tablets orally once daily for 28 days. Treatment may be administered with or without food. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive two matching placebo tablets orally once daily for 28 days. Treatment may be administered with or without food. |
| Name | Type | Description |
|---|---|---|
| GAL-101 Salt | DRUG | GAL-101 salt will be administered orally as two 600 mg tablets, for a total dose of 1200 mg once daily for 28 days. The tablets may be taken with or without food. |
| Placebo | DRUG | Matching placebo will be administered orally as two tablets once daily for 28 days. The tablets may be taken with or without food. |
Inclusion Criteria: * Male or female participants aged 50 to 85 years, inclusive. * Clinical diagnosis of Alzheimer's disease at the mild or moderate dementia stage (Stages 4 or 5) according to the 2018 National Institute on Aging and Alzheimer's Association criteria * Evidence of amyloid-beta path...